About ReBEC

The Brazilian Clinical Trials Registry (ReBEC) is an open-access virtual platform for registering experimental and non-experimental studies involving human beings conducted in Brazilian territory by Brazilian and foreign researchers. ReBEC is a joint project of the Ministry of Health (DECIT/MS), the Pan American Health Organization (PAHO), and the Oswaldo Cruz Foundation (FIOCRUZ). The Executive Committee of ReBEC is composed of the aforementioned institutions and the National Health Surveillance Agency (ANVISA). ReBEC is an important source of information for patients, healthcare professionals, researchers, companies, and research centers. Its support services feature generative artificial intelligence ReBEC@, the first artificial intelligence for clinical trial registration in the world. Learn more

Everything you need to know about ReBEC

Click to access the hotsite

Click to download the PDF version

Instructions for the Registrant

We recommend reading the Registrant's Manual.

1 - Register or log in and fill out the forms normally in Portuguese and English.
For English, if you experience any difficulty, use Google Translate
(or another free translation tool).
2 - Attach the mandatory ethics committee documentation and submit the form.
3 - Save the support number in your WhatsApp contacts. Send a message with your name and username.
It is not necessary or recommended to send your password. 
4 - A reviewer will respond to you. Choose your preferred communication mode:
chat, audio recordings, or scheduled voice call.
5 - Your form will be reviewed in both languages. Follow further instructions to complete approval.

Clinical Research Volunteer

Would you like to become a volunteer in a clinical trial registered in ReBEC?

Access our FAQ to find out how.

10/26/2026  |  Ján Búza  |  The Recursive

https://www.therecursive.com/a-drug-has-to-answer-5-questions-ai-made-only-one-cheap-who-pays-for-the-rest/ 

A monthly column on biotech for founders and builders in Central and Eastern Europe. The first asks why cheaper design hasn't led to cheaper drugs.

AI has made it cheap to design a drug candidate, and yet drugs are getting slower and more expensive to develop. Most people who come to biotech from software assume that once a model has designed the drug, the company has won. The hard part is proving that the drug works in a person, and that proof keeps costing more.

In August, Anthropic reported that its model, Claude, designed proteins that bind 14 of the 15 targets it was given. Of 1,320 designs, 354 worked. Two outside labs, Adaptyv Bio and Twist Bioscience, had to make and measure every protein before anyone knew that. A protein that sticks to its target in a dish is only the first of five steps a drug needs to reach patients.

This column follows a drug through those five steps and asks who pays for each. It draws on what our fund learned from backing 30 companies along that path.

The bill keeps growing
In 2012, Jack Scannell and colleagues showed that the number of drugs approved per billion dollars spent on research, adjusted for inflation, had roughly halved every nine years since 1950. The newest figures point the same way. Deloitte follows the 20 drug companies that spent most on research in 2020 and put their average cost of taking one drug from discovery to launch at $2.67 billion in 2025, up from $2.23 billion a year earlier.

Clinical trials The drugs also take longer. Researchers at Tufts University found that the clinical phase lasted nearly seven months…

10/25/2026  |  Abigail Beaney  |  Clinical Trials Arena

https://www.clinicaltrialsarena.com/news/esmo26-clinical-progress-shifts-a-historically-difficult-pancreatic-cancer-landscape/ 

Revolution Medicines’ impressive daraxonrasib data has spurred hope in the pancreatic cancer space.

Pancreatic cancer has historically presented a poor clinical outlook, offering patients few effective therapeutic options. Because the disease rarely causes early symptoms, diagnoses typically occur at advanced stages, where a dense, fibrous stroma surrounds tumours and shields them from systemic treatment.

Against this backdrop, data from Revolution Medicines Phase III RASolute 302 trial (NCT06625320) showed a near doubling of overall survival (OS) in patients treated with the daily oral RAS(ON) inhibitor Rasonque (daraxonrasib). The US Food and Drug Administration (FDA) approved the drug in August 2026.

The data showed a median overall survival (OS) of 13.2 months in the investigational arm, compared with 6.7 months in the standard-of-care (SOC) arm.

Although a substantial amount of data has already been released, Revolution presented further findings at the 2026 European Society for Medical Oncology (ESMO) Congress.

Trial investigator Dr Zev Wainberg, a professor of medicine and gastrointestinal medical oncology at UCLA, presented a subgroup analysis stratified by tumour mutational status. For the most common mutation, RAS G12D, which accounted for 43.2% of patients in the study, the overall response rate (ORR) was 32%, compared to 11% in the placebo cohort. In RAS G12V, ORR was 24% compared to 9% in the placebo cohort. OS throughout all of the mutation subgroups favoured Rasonque.

Tango Therapeutics combo improves PFS
…

10/24/2026  |  Fedir Kryshtovskyi  |  ua.news

https://ua.news/en/health/u-dr-kongo-startuvali-viprobuvannia-vaktsin-proti-virusu-bundibugio-premium-times-nigeria 

In the city of Bunia in eastern Democratic Republic of the Congo, a clinical trial of vaccines against the Bundibugyo virus, which belongs to the group of pathogens causing Ebola virus disease, has begun. The first study participants received the vaccine on October 23, Premium Times Nigeria reports, citing the World Health Organization.

The Tumaini study
The trial is called Tumaini, which means “hope” in Swahili. It is a Phase II/III clinical study designed to collect data on the safety of the products, the immune response, and their effectiveness against the Bundibugyo virus.

The study will test the Ervebo vaccine, licensed for the prevention of disease caused by Zaire ebolavirus. Its effectiveness against the Bundibugyo virus in humans has not yet been established. The trial is also planned to include two products specifically developed against this virus: one by Moderna and another by the University of Oxford in collaboration with the Serum Institute of India.

Scale of the outbreak
According to organizations supporting the study, as of October 21, 9,552 cases of infection and 4,602 deaths had been confirmed in the DR Congo. The report notes that this is the largest recorded outbreak of the Bundibugyo virus in the country.

The study will have an adaptive design, allowing several vaccines to be assessed under one clinical protocol. Ring vaccination will also be used, primarily for people who had contact with confirmed patients and other individuals at high risk of infection.

The trial is co-led and sponsored by the National Institute of Biomedical…

10/23/2026  |  Tracy Vanderslice  |  European Pharmaceutical Review

https://www.europeanpharmaceuticalreview.com/rethinking-how-investigator-oversight-is-evidenced-in-clinical-trials/2136806.article

As clinical trials grow more complex, evidence of principal investigator oversight requires a more modern, risk-proportionate approach to demonstrate application of clinical and scientific judgment for areas of highest concern in patient safety and data integrity.

Reimagining how investigator oversight is evidenced ultimately centres around patient outcomes. Every hour an investigator spends on review or sign-off of routine, low-risk data is ostensibly less time spent focusing on the most meaningful, high-value data. This paradigm shift is not just a process improvement, it is both an advancement that emphasises a patient-centric, proportionate, critical-to-quality framework – allowing investigators to focus on the signals that matter most – and encourages oversight that is dynamic, predictive and clinically meaningful, providing the most value for patients.

On a complex clinical trial, an investigator may work through several separate systems to review and sign off on data, often long after it was collected. The resulting record confirms that a review took place but reveals little about the rationale and judgment applied to that review, such as a decision related to eligibility criteria or a lab value recognised as an early sign of toxicity. This reasoning is at the very heart of principal investigator (PI) oversight, but it is not captured through a simple signature.

"A better approach would evidence oversight in a way that reflects the clinical and scientific judgment investigators apply in a contemporaneous manner throughout a study”

PI oversight…

10/24/2026  |  AFP

https://www.afp.com/en/ebola-vaccine-trial-begins-dr-congo 

The first clinical trial of an Ebola vaccine in the outbreak gripping the Democratic Republic of Congo began Friday, the head of the World Health Organization said.

The DR Congo's worst-ever Ebola outbreak has passed the 9,700-case mark, with the number of deaths exceeding 4,600.

Among the many challenges facing the response is the lack of any approved vaccines or treatments for the Bundibugyo species of Ebola behind the epidemic.

Ervebo, a vaccine approved for use against the more common Zaire strain of Ebola, will be put through a full-scale human trial in the DRC to see if it offers any cross-protection against Bundibugyo.

The trial began with the first shot of Ervebo being administered in Bunia, the capital of the DRC's northeastern Ituri province, which is the epicentre of the outbreak.

"Science gives us hope. Today, in Bunia DRC, the first participants were vaccinated in a new Ebola vaccine trial called Tumaini, which means 'hope' in Swahili," WHO chief Tedros Adhanom Ghebreyesus said on X.

"This trial will help us understand whether any of the vaccine candidates designed for Bundibugyo virus work," he said, adding that in the meantime, the existing Ervebo vaccine would be tested.

"WHO is supporting this DRC-led effort to find answers and save lives."

The so-called Tumaini trial is a single trial framework that can test the safety, efficacy and immunogenicity of multiple vaccines.

The trial will use a ring vaccination approach: immunising contacts deemed to be at high risk of infection.

It is gearing up to incorporate two Bundibugyo-specific candidate vaccines, which are currently advancing through earlier-stage, smaller-scale clinical trials.

One is a ChAdOx1…